Clinical trials · Washington, D.C., DC
Metastatic Breast Carcinoma clinical trials in Washington, D.C.
We’re tracking 57 recruiting metastatic breast carcinoma studies with a site in or near Washington, D.C. — including Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Washington, D.C.
- NCT05696626RecruitingPhase 3
Test a new pill plus abemaciclib versus standard therapy
This Phase 3 study compares lasofoxifene plus abemaciclib versus fulvestrant plus abemaciclib for ER-positive, HER2-negative breast cancer that has an ESR1 mutation. It looks for better tumor control in people whose cancer has progressed on hormone therapy (an aromatase inhibitor) and who meet specific safety and testing requirements.
Baltimore, MarylandAges 18 years+ - NCT07391774RecruitingPhase 3
Hormone therapy with or without chemo for early breast cancer
This trial tests whether skipping chemotherapy and using only hormone therapy with a drug called ribociclib works as well as chemotherapy followed by hormone therapy with ribociclib for certain early breast cancers that have a low risk of coming back.
Baltimore, MarylandAges 18 years+ - NCT05123482RecruitingPhase 1/Phase 2
Early study of AZD8205 for advanced solid tumors
This Phase 1/2 study tests how safe and effective AZD8205 is for people with advanced or metastatic solid cancers that have come back or spread after standard treatments. It may help by finding the right dose and whether AZD8205 works alone or with another treatment in different cancer types.
Baltimore, MarylandAges 18 years+ - NCT03521830RecruitingPhase 2
Nivolumab and other immunotherapy for advanced basal cell skin cancer
This study tests how well the immunotherapy medicine nivolumab works—either by itself or combined with other immune-boosting drugs—for people with advanced basal cell carcinoma that can’t be removed by surgery or has spread. It’s also looking at what to do if the cancer grows again after an earlier immunotherapy.
Baltimore, MarylandAges 18 years+ - NCT03606967RecruitingPhase 2
Individualized vaccine added to standard treatment for metastatic triple-negative breast cancer
This Phase 2 trial tests whether adding a personalized cancer vaccine to durvalumab (an immunotherapy), tremelimumab (another immunotherapy), and chemotherapy can improve outcomes for people with metastatic triple-negative breast cancer. It may help your immune system recognize your specific tumor features.
Baltimore, MarylandAges 18 years+ - NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
Baltimore, MarylandAges 18 years+ - NCT07340541RecruitingPhase 2
Personalized cancer therapy trial based on tumor markers
This trial tests new treatments that are chosen based on specific markers in your tumor. Researchers want to see if these personalized therapies work better than standard options.
Baltimore, MarylandAges 18 years+ - NCT03786796RecruitingPhase 2
Olaparib for metastatic kidney cancer with specific DNA repair gene changes
This trial tests olaparib (a pill medicine) in people with kidney cancer that has spread and specific DNA “repair” gene mutations. The goal is to see whether this targeted treatment can slow the cancer or help it respond better after prior immunotherapy or blood-vessel–blocking therapy.
Baltimore, MarylandAges 18–120 - NCT06524544RecruitingPhase 3
Pembrolizumab and sacituzumab govitecan for advanced bladder cancer
This trial tests a new drug combination (pembrolizumab and sacituzumab govitecan) against standard treatment for advanced bladder cancer that has spread or cannot be removed by surgery. It's for people who have already tried an immunotherapy drug like pembrolizumab and another drug called enfortumab vedotin.
Fredericksburg, VirginiaAges 18 years+
Hear when a new Metastatic Breast Carcinoma trial opens near Washington, D.C., DC
We’ll email you when one opens near Washington, D.C., DC — at most once a week, no account needed, unsubscribe anytime.
Metastatic Breast Carcinoma trials in other cities
Where these studies are running near Washington, D.C.
Institutions with a site for the recruiting metastatic breast carcinoma studies listed above.
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · 3 studies
- Johns Hopkins University · 2 studies
- Greater Baltimore Medical Center
- Hematology Oncology Associates of Fredericksburg
- Johns Hopkins Hospital
- Research Site
- University of Maryland Greenebaum Comprehensive Cancer Center
- University of Maryland Shore Medical Center
What taking part in a metastatic breast carcinoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Common questions
- Are there metastatic breast carcinoma clinical trials near Washington, D.C.?
- Yes. We're currently tracking 57 recruiting metastatic breast carcinoma studies with a site near Washington, D.C., each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a metastatic breast carcinoma study near Washington, D.C.?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Washington, D.C. to take part?
- Not necessarily. These studies have a site near Washington, D.C., but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a metastatic breast carcinoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New metastatic breast carcinoma studies open near Washington, D.C. regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.